How Will the Market React to Synlogic Inc (SYBX) Stock Getting a Bullish Rating

Synlogic Inc (SYBX) stock is higher by 34.50% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Synlogic Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SYBX!

See Full SYBX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SYBX Stock Today?

Synlogic Inc (SYBX) stock has risen 7.41% while the S&P 500 has fallen -0.11% as of 10:12 AM on Friday, Dec 1. SYBX is up $0.19 from the previous closing price of $2.50 on volume of 4,205 shares. Over the past year the S&P 500 is higher by 11.83% while SYBX has fallen -70.01%. SYBX lost -$12.72 per share in the over the last 12 months. To screen for more stocks like Synlogic Inc click here.

More About Synlogic Inc

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects. Click Here to get the full Stock Report for Synlogic Inc stock.